Potassium IodideCAS# 7681-11-0 |
- Posaconazole hydrate
Catalog No.:BCC4234
CAS No.:1198769-38-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 7681-11-0 | SDF | Download SDF |
PubChem ID | 4875 | Appearance | Powder |
Formula | IK | M.Wt | 166 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO > 10 mM | ||
Chemical Name | potassium;iodide | ||
SMILES | [K+].[I-] | ||
Standard InChIKey | NLKNQRATVPKPDG-UHFFFAOYSA-M | ||
Standard InChI | InChI=1S/HI.K/h1H;/q;+1/p-1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Potassium Iodide Dilution Calculator
Potassium Iodide Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 6.0241 mL | 30.1205 mL | 60.241 mL | 120.4819 mL | 150.6024 mL |
5 mM | 1.2048 mL | 6.0241 mL | 12.0482 mL | 24.0964 mL | 30.1205 mL |
10 mM | 0.6024 mL | 3.012 mL | 6.0241 mL | 12.0482 mL | 15.0602 mL |
50 mM | 0.1205 mL | 0.6024 mL | 1.2048 mL | 2.4096 mL | 3.012 mL |
100 mM | 0.0602 mL | 0.3012 mL | 0.6024 mL | 1.2048 mL | 1.506 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Potassium Iodide
- Azathramycin
Catalog No.:BCC1392
CAS No.:76801-85-9
- 3-Hydroxy-4',5,7-trimethoxyflavanone
Catalog No.:BCN4316
CAS No.:76792-94-4
- 2'-Hydroxydaidzein
Catalog No.:BCN4585
CAS No.:7678-85-5
- GBR 12935
Catalog No.:BCC5381
CAS No.:76778-22-8
- Lupalbigenin
Catalog No.:BCN4314
CAS No.:76754-24-0
- Pyronaridine Tetraphosphate
Catalog No.:BCC1144
CAS No.:76748-86-2
- Decumbenine
Catalog No.:BCC8312
CAS No.:76733-83-0
- Mallorepine
Catalog No.:BCN4317
CAS No.:767-98-6
- 1-Deacetylnimbolinin B
Catalog No.:BCN4313
CAS No.:76689-98-0
- E-64-c
Catalog No.:BCC3588
CAS No.:76684-89-4
- RU 28318, potassium salt
Catalog No.:BCC7146
CAS No.:76676-34-1
- RU 26752
Catalog No.:BCC7531
CAS No.:76676-33-0
- Ronidazole
Catalog No.:BCC4840
CAS No.:7681-76-7
- Pimaricin
Catalog No.:BCN2216
CAS No.:7681-93-8
- Danshensu
Catalog No.:BCN8513
CAS No.:76822-21-4
- Famotidine
Catalog No.:BCC4529
CAS No.:76824-35-6
- 5-BDBD
Catalog No.:BCC7717
CAS No.:768404-03-1
- Przewaquinone A
Catalog No.:BCN3004
CAS No.:76843-23-7
- 6-Hydroxywogonin
Catalog No.:BCN6556
CAS No.:76844-70-7
- 8-Methyl-8-azabicyclo[3.2.1]octane-3,6-diol, 9CI; (3RS,6RS)-form, 3-O-Ac
Catalog No.:BCN1361
CAS No.:7688-76-8
- Olivil 4'-O-glucoside
Catalog No.:BCN7557
CAS No.:76880-93-8
- Camptothecin
Catalog No.:BCN4318
CAS No.:7689-03-4
- Bz-Gly-OH.HCl
Catalog No.:BCC2945
CAS No.:7689-50-1
- Triacsin C
Catalog No.:BCC7377
CAS No.:76896-80-5
Effects of meso-2,3-dimercaptosuccinic acid, potassium iodide and chlorophyll on lead accumulation in male mice.[Pubmed:28220909]
Int J Occup Med Environ Health. 2017 Feb 21;30(1):87-93.
OBJECTIVES: Lead (Pb) pollution is a serious public health problem all over the world, it especially plays severe damage role in children's health. Apart from reducing lead-induced damages, the decrease of lead accumulation is also critical. This study has been the first attempt to investigate effects of meso-2,3-dimercaptosuccinic acid (DMSA), Potassium Iodide (KI) and chlorophyll (Chl) on lead accumulation in male mice. MATERIAL AND METHODS: Eighty healthy Kunming male mice were selected and divided randomly into 8 groups. They were treated with lead acetate (PbAc) intraperitoneally, individually and in combination with the DMSA, KI or Chl once daily for 5 days. Meanwhile, the control group was treated with normal saline during the whole exposure period. On 30th day, mice were sacrificed and lead concentrations were detected in the whole blood, livers, kidneys, and testicles of mice by means of the graphite furnace atomic absorption spectrometry. RESULTS: In comparison with the control group, lead concentrations increased in mice treated with the PbAc and DMSA, KI and Chl diminished lead accumulation in the whole blood, livers, and kidneys. Chl had specifically the same effects on lead concentrations in the testicles of male mice. CONCLUSIONS: Potassium Iodide and Chl, as food additives, had the same effects as the DMSA to reduce lead accumulation in male mice effectively. Our results provided experimental evidence in vivo for the preventive measures of lead poisoning. Int J Occup Med Environ Health 2017;30(1):87-93.
Potassium Iodide Potentiates Broad-Spectrum Antimicrobial Photodynamic Inactivation Using Photofrin.[Pubmed:28207234]
ACS Infect Dis. 2017 Apr 14;3(4):320-328.
It is known that noncationic porphyrins such as Photofrin (PF) are effective in mediating antimicrobial photodynamic inactivation (aPDI) of Gram-positive bacteria or fungi. However, the aPDI activity of PF against Gram-negative bacteria is accepted to be extremely low. Here we report that the nontoxic inorganic salt Potassium Iodide (KI) at a concentration of 100 mM when added to microbial cells (10(8)/mL) + PF (10 muM hematoporphyrin equivalent) + 415 nm light (10 J/cm(2)) can eradicate (>6 log killing) five different Gram-negative species (Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Proteus mirabilis, and Acinetobacter baumannii), whereas no killing was obtained without KI. The mechanism of action appears to be the generation of microbicidal molecular iodine (I2/I3(-)) as shown by comparable bacterial killing when cells were added to the mixture after completion of illumination and light-dependent generation of iodine as detected by the formation of the starch complex. Gram-positive methicillin-resistant Staphylococcus aureus is much more sensitive to aPDI (200-500 nM PF), and in this case potentiation by KI may be mediated mainly by short-lived iodine reactive species. The fungal yeast Candida albicans displayed intermediate sensitivity to PF-aPDI, and killing was also potentiated by KI. The reaction mechanism occurs via singlet oxygen ((1)O2). KI quenched (1)O2 luminescence (1270 nm) at a rate constant of 9.2 x 10(5) M(-1) s(-1). Oxygen consumption was increased when PF was illuminated in the presence of KI. Hydrogen peroxide but not superoxide was generated from illuminated PF in the presence of KI. Sodium azide completely inhibited the killing of E. coli with PF/blue light + KI.
Effect of Silver Diamine Fluoride and Potassium Iodide Treatment on Secondary Caries Prevention and Tooth Discolouration in Cervical Glass Ionomer Cement Restoration.[Pubmed:28178188]
Int J Mol Sci. 2017 Feb 6;18(2). pii: ijms18020340.
This study investigated the effect of silver diamine fluoride (SDF) and Potassium Iodide (KI) treatment on secondary caries prevention and tooth discolouration in glass ionomer cement (GIC) restoration. Cervical GIC restorations were done on 30 premolars with: Group 1, SDF + KI; Group 2, SDF (positive control); Group 3, no treatment (negative control). After cariogenic biofilm challenge, the demineralisation of dentine adjacent to the restoration was evaluated using micro-computed tomography (micro-CT) and Fourier transform infrared (FTIR) spectroscopy. The colour of dentine adjacent to the restoration was assessed using CIELAB system at different time points. Total colour change (E) was calculated and was visible if E > 3.7. Micro-CT showed the outer lesion depths for Groups 1, 2 and 3 were 91 +/- 7 microm, 80 +/- 7 microm and 119 +/- 8 microm, respectively (p < 0.001; Group 2 < Group 1 < Group 3). FTIR found that there was a significant difference in amide I-to-hydrogen phosphate ratio among the three groups (p < 0.001; Group 2 < Group 1 < Group 3). E of Groups 1, 2 and 3 after biofilm challenge were 22.5 +/- 4.9, 70.2 +/- 8.3 and 2.9 +/- 0.9, respectively (p < 0.001; Group 3 < Group 1 < Group 2). SDF + KI treatment reduced secondary caries formation on GIC restoration, but it was not as effective as SDF treatment alone. Moreover, a perceptible staining on the restoration margin was observed, but the intensity of discolouration was less than that with solely SDF treatment.
Palmoplantar pustulosis and pustulotic arthro-osteitis treatment with potassium iodide and tetracycline, a novel remedy with an old drug: a review of 25 patients.[Pubmed:28369847]
Int J Dermatol. 2017 Aug;56(8):889-893.
BACKGROUND: The use of Potassium Iodide (KI) to treat palmoplantar pustulosis (PPP) and pustulotic arthro-osteitis (PAO) has not previously been reported. Here, we report the first successful treatment of PPP and PAO with KI. PATIENT AND METHODS: Among 25 patients with PPP, seven had an associated PAO. All patients were administered 900 mg KI three times per day for 3 months. Overall, 12 patients received this medical treatment for the first time or had >6 months interval since the last therapy for PPP. The other 13 patients who were nonresponsive to tetracycline for >3 months prior to KI treatment were treated with a combination of KI and tetracycline. All seven patients with PAO were included in the tetracycline and KI-treated group. RESULTS: More than 70% of patients demonstrated complete clearance or >/=50% improvement in palmoplantar pustular psoriasis area and severity index (PPPASI) from baseline. In the group with <50% improvement in PPPASI from baseline, all except one patient were smokers. In the KI with tetracycline treatment group, approximately 80% demonstrated improvement. At the end of 3 months, there was remission of arthralgia in five out of seven PPP patients with PAO. CONCLUSIONS: Treatment with KI and/or its combination with tetracycline may be a useful treatment for PPP/PAO. Smoking may affect the effectiveness of these treatment modalities.